FR2665449B1 - Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant. - Google Patents

Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.

Info

Publication number
FR2665449B1
FR2665449B1 FR9009917A FR9009917A FR2665449B1 FR 2665449 B1 FR2665449 B1 FR 2665449B1 FR 9009917 A FR9009917 A FR 9009917A FR 9009917 A FR9009917 A FR 9009917A FR 2665449 B1 FR2665449 B1 FR 2665449B1
Authority
FR
France
Prior art keywords
von willebrand
factor
willebrand factor
high purity
manufacturing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9009917A
Other languages
English (en)
Other versions
FR2665449A1 (fr
Inventor
Bernard Dazey
Mohamed Hamsany
Gerard Vezon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AQUITAINE DEVELOPP TRANSF SANG
Original Assignee
AQUITAINE DEVELOPP TRANSF SANG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9399373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2665449(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AQUITAINE DEVELOPP TRANSF SANG filed Critical AQUITAINE DEVELOPP TRANSF SANG
Priority to FR9009917A priority Critical patent/FR2665449B1/fr
Priority to EP91402124A priority patent/EP0469985B1/fr
Priority to DK91402124.1T priority patent/DK0469985T3/da
Priority to DE199191402124T priority patent/DE469985T1/de
Priority to ES91402124T priority patent/ES2038095T3/es
Priority to DE69125764T priority patent/DE69125764T2/de
Priority to AT91402124T priority patent/ATE152128T1/de
Priority to JP3194443A priority patent/JP2559645B2/ja
Priority to US07/739,452 priority patent/US5252710A/en
Publication of FR2665449A1 publication Critical patent/FR2665449A1/fr
Priority to US08/016,807 priority patent/US5760183A/en
Publication of FR2665449B1 publication Critical patent/FR2665449B1/fr
Application granted granted Critical
Priority to GR970401765T priority patent/GR3024115T3/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
FR9009917A 1989-02-17 1990-08-02 Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant. Expired - Fee Related FR2665449B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR9009917A FR2665449B1 (fr) 1990-08-02 1990-08-02 Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
AT91402124T ATE152128T1 (de) 1990-08-02 1991-07-30 Verfahren zur herstellung des von willebrand- faktors von höchster reinheit
DK91402124.1T DK0469985T3 (da) 1990-08-02 1991-07-30 Fremgangsmåde til fremstilling af von Willebrand-faktor med meget høj renhed.
DE199191402124T DE469985T1 (de) 1990-08-02 1991-07-30 Verfahren zur herstellung des von willebrand-faktors von hoechster reinheit.
ES91402124T ES2038095T3 (es) 1990-08-02 1991-07-30 Procedimiento para fabricar factor von willebrand con un grado de pureza muy alto.
DE69125764T DE69125764T2 (de) 1990-08-02 1991-07-30 Verfahren zur Herstellung des Von Willebrand-Faktors von höchster Reinheit
EP91402124A EP0469985B1 (fr) 1990-08-02 1991-07-30 Procédé de fabrication de facteur Von Willebrand ayant une très haute pureté
US07/739,452 US5252710A (en) 1990-08-02 1991-08-02 Process for manufacturing von Willebrand factor
JP3194443A JP2559645B2 (ja) 1990-08-02 1991-08-02 抗血友病因子（第ＶＩＩＩｃ因子）をほとんど含まない高純度のフォン・ヴィレブラント因子を生成する方法
US08/016,807 US5760183A (en) 1989-02-17 1993-02-11 Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
GR970401765T GR3024115T3 (en) 1990-08-02 1997-07-16 Process for manufacturing von Willebrand factor having a very high purity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9009917A FR2665449B1 (fr) 1990-08-02 1990-08-02 Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.

Publications (2)

Publication Number Publication Date
FR2665449A1 FR2665449A1 (fr) 1992-02-07
FR2665449B1 true FR2665449B1 (fr) 1995-04-14

Family

ID=9399373

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9009917A Expired - Fee Related FR2665449B1 (fr) 1989-02-17 1990-08-02 Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.

Country Status (9)

Country Link
US (1) US5252710A (fr)
EP (1) EP0469985B1 (fr)
JP (1) JP2559645B2 (fr)
AT (1) ATE152128T1 (fr)
DE (2) DE469985T1 (fr)
DK (1) DK0469985T3 (fr)
ES (1) ES2038095T3 (fr)
FR (1) FR2665449B1 (fr)
GR (1) GR3024115T3 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760183A (en) * 1989-02-17 1998-06-02 Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
KR970060724A (ko) * 1996-01-16 1997-08-12 김광호 백업용 배터리 동작의 표시방법 및 그 감지회로
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
ATE365052T1 (de) 1999-02-22 2007-07-15 Univ Connecticut Neue albuminfreie faktor viii formulierungen
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
ATE430578T1 (de) * 1999-12-24 2009-05-15 Chemo Sero Therapeut Res Inst Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
KR101131411B1 (ko) 2003-07-22 2012-07-05 넥타르 테라퓨틱스 중합체 알코올로부터 관능화된 중합체의 제조 방법
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
WO2007011802A1 (fr) 2005-07-18 2007-01-25 Nektar Therapeutics Al, Corporation Procede de preparation de polymeres fonctionnalises ramifies en utilisant des noyaux de polyol ramifies
CA2726942A1 (fr) * 2008-06-04 2009-12-10 Bayer Healthcare Llc Muteines du facteur viii pour le traitement de la maladie de von willebrand
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
IT1396528B1 (it) 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4170590A (en) * 1974-12-14 1979-10-09 Biotest-Serum-Institut Gmbh Ion exchanger treatment of citrate-stabilized plasma
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
FR2570276B1 (fr) * 1984-09-18 1987-09-04 Immunotech Sa Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant
JPS63108000A (ja) * 1986-05-15 1988-05-12 Green Cross Corp:The 第８因子の精製方法
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
NL8701915A (nl) * 1987-08-14 1989-03-01 Waander Riethorst Adsorbensmateriaal en toepassing daarvan voor het isoleren van stollingsfaktoren.
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
FR2650393A1 (fr) * 1989-07-28 1991-02-01 Herault Ctre Rgl Transfusion S Methode de purification du facteur vii (f viii) par chromatographie echangeuse d'ions

Also Published As

Publication number Publication date
FR2665449A1 (fr) 1992-02-07
ES2038095T3 (es) 1997-09-16
DK0469985T3 (da) 1997-10-20
US5252710A (en) 1993-10-12
DE469985T1 (de) 1992-10-15
ATE152128T1 (de) 1997-05-15
JP2559645B2 (ja) 1996-12-04
EP0469985A1 (fr) 1992-02-05
DE69125764T2 (de) 1997-11-13
GR3024115T3 (en) 1997-10-31
EP0469985B1 (fr) 1997-04-23
JPH04234400A (ja) 1992-08-24
ES2038095T1 (es) 1993-07-16
DE69125764D1 (de) 1997-05-28

Similar Documents

Publication Publication Date Title
FR2665449B1 (fr) Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
EP0391526A3 (fr) Procédé de purification d'anticorps
IL228987A0 (en) Purification of proteins using ion exchange chromatography
ITFI920078A1 (it) Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
LV10053A (lv) Kompleksa "Faktors-YIII + fon Villebranda faktors" koncentrata iegusanas metode
DE3686470D1 (de) Verfahren zur herstellung des alpha-1-proteinase-inhibitors.
ATE91152T1 (de) Gereinigte protein a-zusammensetzungen und verfahren zu ihrer herstellung.
SE8402861D0 (sv) Rening av biologiskt material
DE69311337D1 (de) Verfahren zur Reinigung von Proteinen
HUT64777A (en) Method for producing virus-safe vii factor of high purity
DK237181A (da) Fremgangsmaade til berigelse af nikkomycinblandinger
FR2632302B1 (fr) Procede de recuperation d'acide citrique a partir d'une liqueur en contenant
AU6487286A (en) Antihemophilic factor by cold precipitation
ATE388722T1 (de) THERAPEUTISCHE FRAGMENTE DES ßVON WILLEBRANDß FAKTORS
FR2644064B1 (fr) Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
KR960004367A (ko) α1-안티카이모트립신의 제조방법
DE69303941T2 (de) Verfahren zur Herstellung von hochreinem Fibrinogen
ES2093780T3 (es) Procedimiento para la produccion de bisfenol a.
ATE270327T1 (de) Verfahren zur präparation von humanem aktiviertem protein c
KR940013535A (ko) 순수한 인 혈액 응고 제2인자 및 제9인자의 정제 방법
JPS6486871A (en) Method for separating and purifying recombinant protein

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20090430